Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Persistent Diffuse Diabetic Macular Edema

American Journal of Ophthalmology

Volumn 146, Issue 6, 2008, Pages 974-

  Kumar, Vinod ^a   Ghosh, Basudeb ^a   Raina, Usha K ^a   Goel, Neha ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

DIABETIC MACULAR EDEMA; HUMAN; LETTER; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; RETINA FOVEA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 56249126386     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.08.013     Document Type: Letter

References (3)

1. Shimura M., Nakazawa T., Yasuda K., et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 145 (2008) 854-861
2. Sutter F.K.P., Simpson J.M., and Gillies M.C. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology 111 (2004) 2044-2049
3. Hartioglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005